HighTower Advisors
GALT icon

HighTower Advisors’s Galectin Therapeutics GALT Stock Holding History

HighTower Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,000
Closed -$2K – 2264
2018
Q3 		$2K Buy
+1,000
New +$5.5K ﹤0.01% 2246

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HighTower Advisors's GALT Position: Q2 2026 in Review

HighTower Advisors increased its Galectin Therapeutics (GALT) stake by 0.8% in Q2 2026, buying an estimated $1.94K and bringing the position to 94,125 shares worth $437K. The position accounts for ﹤0.01% of the portfolio, ranked #2869.

HighTower Advisors first reported a position in GALT in Q3 2018 and has held it in 8 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • HighTower Advisors held 94,125 shares of Galectin Therapeutics worth $437K as of Q2 2026.
  • HighTower Advisors bought 750 Galectin Therapeutics shares in Q2 2026, an estimated $1.94K.
  • Galectin Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2869 holding.
  • HighTower Advisors first reported a position in Galectin Therapeutics in Q3 2018 and has held it in 8 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.